A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children.

@article{Lau2002ACO,
  title={A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children.},
  author={Yu Lung Lau and S J Rupert Vessey and Ivan Siu Fung Chan and T L Lee and L M Huang and C. Lee and T. -Y. Lin and Bee Wah Lee and Kow Kwan and Siti M Kasim and Christina Y Chan and Karen M. Kaplan and Daniel J Distefano and Anna L Harmon and Amy Golie and Jonathan S. Hartzel and Jin Xu and Shu Zhen Li and Holly Matthews and Jerald C. Sadoff and Alan Shaw},
  journal={Vaccine},
  year={2002},
  volume={20 23-24},
  pages={2942-9}
}
This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (approximately 50,000 plaque forming units (PFU), Group A or approximately 16,000 PFU, Group B) or 1 dose of VARILRIX, (approximately 40,000 PFU/dose, Group C). Safety profiles in each… CONTINUE READING